三水杨酸胆碱镁(Choline Magnesium Trisalicylate) - 在研适应症：骨关节炎，类风湿关节炎_专利_临床

概要

基本信息

药物类型

小分子化药

别名

Tricosal

靶点-

作用机制-

治疗领域

免疫系统疾病皮肤和肌肉骨骼疾病

在研适应症

骨关节炎类风湿关节炎

非在研适应症-

原研机构-

在研机构-

非在研机构-

最高研发阶段批准上市

首次获批日期-

最高研发阶段(中国)批准上市

特殊审评-

登录后查看时间轴

结构

分子式C26H29MgNO10

InChIKeyFQCQGOZEWWPOKI-UHFFFAOYSA-K

CAS号64425-90-7

关联

3

项与三水杨酸胆碱镁相关的临床试验

NCT01009931 / Terminated临床2期IIT

A Phase II Study of 12-O-tetradecanoylphorbol-13-acetate (TPA) Plus Dexamethasone & Choline Magnesium Trisalicylate in the Treatment of Patients With Relapsed/Refractory Acute Myelogenous Leukemia

This phase II trial is studying the side effects and how well giving tetradecanoylphorbol acetate together with dexamethasone and choline magnesium trisalicylate works in treating patients with relapsed or refractory acute myeloid leukemia.

开始日期2011-03-01

申办/合作机构

Rutgers State University of New Jersey

[+3]

NCT02144675 / Completed临床2期IIT

A Randomized Phase II Study of Nuclear Factor-kappa B (NF-κB) Inhibition During Induction Chemotherapy for Patients With Acute Myelogenous Leukemia

This randomized phase II trial studies how well choline magnesium trisalicylate with idarubicin and cytarabine works in treating patients with acute myeloid leukemia. Drugs used in chemotherapy, such as choline magnesium trisalicylate, idarubicin, and cytarabine, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. It is not yet know whether choline magnesium trisalicylate and combination chemotherapy is more effective than combination chemotherapy alone in treating patients with acute myeloid leukemia.

开始日期2009-01-01

申办/合作机构

Rutgers State University of New Jersey

[+2]

NCT00156299 / Terminated临床1期IIT

A Pilot Study of Nuclear Factor-kappa B (NFkB) Inhibition During Induction Chemotherapy for Patients With Acute Myelogenous Leukemia (AML)

RATIONALE: Studying samples of blood from patients with cancer in the laboratory may help doctors learn more about changes that occur in cancer cells. It may also help doctors understand how cancer cells respond to treatment with choline magnesium trisalicylate.
PURPOSE: This pilot clinical trial is studying gene expression in cancer cells during chemotherapy and the safety of choline magnesium trisalicylate in treating patients with newly diagnosed acute myeloid leukemia.

开始日期2003-03-01

申办/合作机构

Rutgers State University of New Jersey

[+1]

100 项与三水杨酸胆碱镁相关的临床结果

登录后查看更多信息

100 项与三水杨酸胆碱镁相关的转化医学

登录后查看更多信息

100 项与三水杨酸胆碱镁相关的专利（医药）

登录后查看更多信息

37

项与三水杨酸胆碱镁相关的文献（医药）

2017-05-04·Leukemia & Lymphoma

Choline-magnesium trisalicylate modulates acute myelogenous leukemia gene expression during induction chemotherapy

Letter

作者: Walton, Kelly ; Patel, Vimal ; Medina, Daniel ; Gharibo, Mecide ; Aisner, Joseph ; David, Kevin ; Strair, Roger ; Lin, Yong ; Bannerji, Rajat ; Schaar, Dale ; Rabson, Arnold B.

Nuclear factor kappa B (NF-κB) is constitutively expressed in many primary acute myelogenous leukemia (AML) and leukemic stem cell (LSC) samples. Inhibition of nuclear NF-κB ex vivo results in cyto...

2008-11-15·Clinical Cancer Research1区 · 医学

Nuclear Factor-κB Modulation in Patients Undergoing Induction Chemotherapy for Acute Myelogenous Leukemia

1区 · 医学

Article

作者: Anand, Monika ; Lin, Yong ; Gharibo, Mecide ; Strair, Roger K. ; Lin, Hsin-Ching ; Balsara, Binaifer ; Dudek, Liesel ; Rabson, Arnold ; Goodell, Lauri ; Schaar, Dale ; Medina, Daniel J. ; Rubin, Arnold ; Harrison, Jonathan ; Aisner, Joseph

AbstractPurpose: Nuclear factor-κB (NF-κB) is constitutively expressed in many acute myelogenous leukemia (AML) cells and AML stem cells. Ex vivo treatment of AML cells with inhibitors of NF-κB results in diminished AML cell survival and enhances the cytotoxic effects of chemotherapeutic agents. The purpose of this study was to determine if standard anti-inflammatory agents modulate AML cell nuclear NF-κB when administered in conjunction with induction chemotherapy.Experimental Design: Patients with newly diagnosed AML were treated with dexamethasone, choline magnesium trisalicylate, or both for 24 hours prior to and 24 hours following initiation of standard induction chemotherapy. AML cell nuclear NF-κB was measured at baseline, 24, and 48 hours.Results: Choline magnesium trisalicylate ± dexamethasone decreased nuclear NF-κB, whereas dexamethasone alone was associated with an increase in nuclear NF-κB in AML cells.Conclusions: These results show the feasibility of NF-κB modulation in conjunction with induction chemotherapy for patients with AML using inexpensive readily available medications. A follow-up study to determine the effects of NF-κB modulation on clinical end points is warranted.

2004-01-01·Current Allergy and Asthma Reports2区 · 医学

Adverse respiratory reactions to aspirin and nonsteroidal anti-inflammatory drugs

2区 · 医学

Review

作者: Simon, Ronald A

Aspirin-exacerbated respiratory disease (AERD) is an adult-onset condition that manifests as asthma, rhinosinusitis/nasal polyps, and sensitivity to aspirin and other cyclooxygenase-1 (COX-1)-inhibitor nonsteroidal anti-inflammatory drugs (NSAIDs). There is no cross-sensitivity to highly selective COX-2 inhibitors. AERD is chronic and does not improve with avoidance of COX-1 inhibitors. The diagnosis of AERD is made through provocative challenge testing. Following a positive aspirin challenge, patients can be desensitized to aspirin and NSAIDs. The desensitized state can be maintained indefinitely with continued daily administration. After desensitization, there is an approximately 48-hour refractory period to adverse effects from aspirin. The pathogenesis of AERD remains unknown, but these patients have been shown to have multiple abnormalities in arachidonic acid metabolism and in cysteinyl leukotriene 1 receptors. AERD patients can take up to 650 mg of acetaminophen for analgesic or antipyretic relief. Patients can also use weak COX-1 inhibitors, such as sodium salicylate or choline magnesium trisalicylate. Treatment of AERD patients with antileukotriene medications has been helpful but not preferential when compared with non-AERD patients. An alternative treatment for many AERD patients is aspirin desensitization. This is particularly effective in reducing upper-airway mucosal congestion, nasal polyp formation, and systemic steroids.

100 项与三水杨酸胆碱镁相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D07694	-	-	DB01401

研发状态

10 条最早获批的记录,

登录

后查看更多信息

适应症	国家/地区	公司	日期
骨关节炎	中国	-	-
类风湿关节炎	中国	-	-

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT02144675 (CTgov)	临床2期	伴del(5q)成人急性髓系白血病 \| 急性髓单核细胞白血病 \| 伴有 11q23 异常的急性髓系白血病 \| 成人急性单核细胞白血病 \| 急性红细胞白血病 \| 急性巨核细胞白血病	27	laboratory biomarker analysis+choline magnesium trisalicylate+Cytarabine+idarubicin (Arm I (Choline Magnesium Trisalicylate and Chemotherapy))	選構壓淵鑰淵襯艱夢憲(鑰衊選製餘鑰積艱鏇顧) = 鬱蓋選艱顧鹽壓憲壓範壓獵遞繭範遞鹹簾艱鏇 (壓範遞醖窪繭蓋繭窪衊, 繭觸願遞觸鏇壓憲衊鬱 ~ 憲鬱獵築鬱遞艱糧衊鹽) 更多	-	2018-07-24
NCT02144675 (CTgov)	临床2期		27	laboratory biomarker analysis+Cytarabine+idarubicin (Arm II (Chemotherapy))	選構壓淵鑰淵襯艱夢憲(鑰衊選製餘鑰積艱鏇顧) = 顧簾廠廠觸鬱鹹餘鹹遞壓獵遞繭範遞鹹簾艱鏇 (壓範遞醖窪繭蓋繭窪衊, 觸繭簾範膚壓觸簾憲夢 ~ 選餘艱積齋蓋壓餘製構) 更多	-	2018-07-24
NCT01009931 (CTgov)	临床2期	急性髓性白血病	1	Choline magnesium trisalicylate+12-O-tetradecanoylphorbol-13-acetate+dexamethasone	積鏇選鑰鹽鏇憲鏇鏇窪(製壓範遞鹹築選鏇糧鑰) = 簾廠鹽糧選鹹窪襯範鑰餘醖觸鏇遞網衊艱簾積 (襯鏇構選選選願憲選製, 艱願鬱夢蓋鬱顧淵鑰窪 ~ 齋範範構襯簾鹹鑰願製) 更多	-	2015-06-22